Epidemiology and management of bleeding in patients using vitamin K antagonists

Journal of Thrombosis and Haemostasis

Volumn 7, Issue SUPPL. 1, 2009, Pages 103-106

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Coumadin; Hemorrhage; Vitamin K antagonists; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; CYTOCHROME P450 2C9; FRESH FROZEN PLASMA; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS; VITAMIN K; WARFARIN;

EID: 67849103780     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03389.x     Document Type: Review

References (42)

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-11.
2. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 257S-98S.
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82.
4. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. Lancet Neurol 2007; 6: 115-24.
5. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
6. Vink R, Kraaijenhagen RA, Hutten BA, Levi M. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: A meta-analysis. J.Am Coll Cardiol 2003; 42: 2042-8.
7. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
8. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
9. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: Prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 160S-98S.
11. Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J. Clin Pathol 2002; 55: 845-9.
12. Poller L, Shiach CR, MacCallum PK. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998; 352: 1505-9.
13. Ageno W, Johnson J, Nowacki B, Turpie AG. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost 2000; 83: 849-52.
14. Levi M. Self-management of anticoagulation. Expert Rev Cardiovasc Ther 2008; 6: 979-85.
15. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303-12.
16. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-52.
17. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
18. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: E312.
19. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471-6.
20. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9: 215-7.
21. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome. Ann Intern Med 2005; 143: 241-50.
22. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ 2006; 333: 726.
23. Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: A population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-81.
24. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165: 189-92.
25. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?'. Lancet 2005; 365: 82-93.
26. Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb Haemost 2008; 100: 1047-51.
27. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther 2004; 26: 1470-8.
28. Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY. Outcomes in the management of atrial fibrillation: Clinical trial results can apply in practice. Intern Med J 2001; 31: 329-36.
29. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 2009; 4: 137-45.
30. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy. J. Thromb Haemost 2006; 4: 1853-63.
31. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med 2009; 150: 293-300.
32. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137: 251-4.
33. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: A prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-73.
34. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, de Vries-Goldschmeding HJ, Rakers E, Levi M. Invasive procedures in the outpatient setting: Managing the short-acting acenocoumarol and the long-acting phenprocoumon. Thromb Haemost 2007; 98: 747-55.
35. Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: A systematic review. Haematologica 2004; 89: 857-62.
36. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc 2007; 82: 82-92.
37. Van AL, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy. Thromb Res 2006; 118: 313-20.
38. Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: Where are the evidence-based data? J Thromb Haemost 2006; 4: 963-6.
39. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal. J Thromb Haemost 2008; 6: 622-31.
40. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191-5.
41. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006; 26: 1091-8.
42. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis. Blood Coagul Fibrinolysis 2003; 14: 469-77.